Journal article

Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy

FM Russell, PV Licciardi, A Balloch, V Biaukula, L Tikoduadua, JR Carapetis, J Nelson, AWJ Jenney, L Waqatakirewa, S Colquhoun, YB Cheung, MLK Tang, EK Mulholland

Vaccine | ELSEVIER SCI LTD | Published : 2010

Grants

Awarded by U.S. NIAID


Funding Acknowledgements

The authors wish to sincerely thank all the FiPP staff and families participating in the study, the Fiji Ministry of Health, CWMH laboratory and paediatric department, and the many other people who contributed to the study including: Amanda O'Brien, Kathryn Bright, Amy Bin Chen, Timothy Gemetzis, Amy Auge, Katherine Gilbert, Evan Willis, Philip Greenwood, Beth Temple, Vanessa Johnston, Loretta Thorn, Porter Anderson, Brian Greenwood, George Siber, David Klein, Elizabeth Horigan, Farukh Khambaty, and the members of the DSMB. Funding was provided by the U.S. NIAID (grant number RO1 AI 52337) and the Australian National Health and Medical Research Council. Pneumovax (TM) was kindly donated by CSL Biotherapies, Australia. The co-administered Tritanrix (TM)-HepB (TM) and Hiberix (TM) vaccines were kindly donated by GlaxoSmithKline. Clinicaltrials.gov number NCT00170612.